Results 181 to 190 of about 42,363 (276)

Hypoalbuminemia as a predictor of mortality in patients with acute cholangitis: A systematic review and meta-analysis. [PDF]

open access: yesWorld J Gastrointest Pathophysiol
Khan RTY   +8 more
europepmc   +1 more source

Development of the Weight‐Tiered Q3W Regimen of Amivantamab in Combination With Carboplatin‐Pemetrexed in EGFR‐Mutated Non‐Small Cell Lung Cancer

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 6, June 2026.
ABSTRACT Amivantamab, a bispecific antibody targeting epidermal growth factor and mesenchymal‐epithelial transition receptors, was initially approved under accelerated approval as a monotherapy for second‐line treatment of non‐small cell lung cancer (NSCLC) with exon 20 insertion mutations.
Dongfen Yuan   +17 more
wiley   +1 more source

Evaluation of the HALP Score in the Distinction Between Fetal Growth Restriction and Small for Gestational Age

open access: yesReproductive, Female and Child Health, Volume 5, Issue 2, June 2026.
ABSTRACT Objective To assess whether the hemoglobin–albumin–lymphocyte–platelet (HALP) score distinguishes fetal growth restriction (FGR) from small for gestational age (SGA) and its association with composite adverse perinatal outcome (CAPO). Method This retrospective study included 444 singleton pregnancies (214 FGR; 230 SGA) at a tertiary center ...
Murat İbrahim Toplu   +6 more
wiley   +1 more source

Prospective Multicenter Observational Study of Anlotinib in Advanced Non‐Small Cell Lung Cancer: Real‐World Evidence From China

open access: yesThoracic Cancer, Volume 17, Issue 11, June 2026.
In this prospective real‐world study, anlotinib demonstrated meaningful efficacy and manageable safety in advanced NSCLC. ABSTRACT Background Anlotinib has shown remarkable efficacy in later‐line treatment of advanced non‐small cell lung cancer (NSCLC).
Jinlin Wang   +17 more
wiley   +1 more source

Clinical Factors Associated With Non‐Completion of Durvalumab Maintenance Therapy After Chemoradiotherapy in Patients With Locally Advanced Non‐Small Cell Lung Cancer: A Single‐Center Retrospective Study

open access: yesThoracic Cancer, Volume 17, Issue 12, June 2026.
Among 80 patients with locally advanced NSCLC receiving durvalumab after CCRT, 44 patients (55%) did not complete 12 months of treatment. Lower A/G ratio and higher RDW‐SD before durvalumab initiation may serve as exploratory signals for non‐completion, closer monitoring, and supportive care planning.
Masaaki Kotake   +4 more
wiley   +1 more source

Preoperative Pulmonary Function and Postoperative Pulmonary Complications in Noncardiac Surgery: A Propensity Score–Weighted Analysis

open access: yesThoracic Cancer, Volume 17, Issue 12, June 2026.
Abnormal preoperative pulmonary function tests and lower FEV1 were independently associated with an increased risk of postoperative pulmonary complications in patients undergoing noncardiac surgery. ABSTRACT Background Postoperative pulmonary complications (PPCs) increase surgical morbidity and mortality.
Sung Ae Cho, Hee Eun Kim, Moon Ok Lee
wiley   +1 more source

Home - About - Disclaimer - Privacy